Biosimilars: What they are and their use in oncology

Cancer and Chemotherapy Reviews

Volumn 6, Issue 3, 2011, Pages 141-148

  Grande, Enrique ^a   Carrato, Alfredo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anticancer agents; Biological products; Biosimilars; Drug approval; European Union; Hematologic agents

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR; EP 2006; EPOETIN ALPHA HEXAL; FILGRASTIN HEXAL; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; INSULIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANEMIA; CANCER THERAPY; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; MEDICAL LITERATURE; ONCOLOGY; PHARMACEUTICAL CARE; PHYSICAL CHEMISTRY; PUBLICATION; REVIEW; RISK MANAGEMENT;

EID: 81355123577     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46: 765-81.
2. Uyl-de Groot CA, de Groot S, Steenhoel A. The economics of improved cancer survival rates: better outcomes, higher costs. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10:283-92.*Summary of concerns related to increasing costs of screening, diagnosis and the treatment of cancer nowadays.
3. Albreht T, McKee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. Eur J Cancer. 2008;44:1451-6.
4. Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011;9: 934-43.
5. Bach P. Limits in Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-33.
6. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044-8.
7. Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-19. (Pubitemid 38944397)
8. Mulcahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape News, 14 July 2009. Available from: http://www.medscape.com/ viewarticle/705689 (accessed 26 August 2011).
9. Perrin S. Therapeutic decision making in oncology. Hosp Pharm Europe. 2010;52:36-7.
10. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71:1527-36. *Updated summary of the submission requirements that biosimilars are facing with stakeholders, developers and health authorities.
11. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010;10:1011-18.
12. Weise M, Bielsky MC, De Smet K, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29:690-3.
13. Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23:3731-7.
14. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharmaceut Sci. 2007;10:405-10. (Pubitemid 350065566)
15. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: 2006. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific- guideline/2009/09/WC500003953.pdf (accessed 8 August 2011).
16. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK: 2006. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/ 09/WC500003920. pdf (accessed 8th August 2011).
17. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK: 2007. Available from: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/ 09/WC50000 3946.pdf (accessed 8 August 2011).
18. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). London, UK: 2010. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 04/WC500089474.pdf (accessed 8 August 2011).
19. European Medicines Agency. Guideline on similar medicinal products containing somatropin. London, UK: 2006. Available from: http:// www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/ WC500003956.pdf (accessed 26 August 2011).
20. European Medicines Agency. Guideline on similar medicinal products containing recombinant granulocyte-colony stimulating factor. London, UK: 2006. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/ Scientific-guideline/2009/09/ WC500003955.pdf (accessed 26 August 2011).
21. European Medicines Agency. Guideline on similar medicinal products containing recombinant human soluble insulin. London, UK: 2006. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/ 09/WC500003957.pdf (accessed 26 August 2011).
22. European Medicines Agency. Guideline on similar medicinal products containing recombinant interferon alpha. London, UK: 2006. Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/ 09/WC500003931.pdf (accessed 26 August 2011).
23. European Medicines Agency. Guideline on similar biological medicinal products containing low-molecular-weight -heparins. London, UK: 2008. Available from: http://www.ema.europa.eu/docs/en-GB/document-l ibrary/Scient i f ic-guideline/2009/09/WC500003928.pdf (accessed 26 August 2011).
24. Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice. 2009;15:34-40.
25. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347-57.
26. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotech. 2010;28:28-31.*This article summarizes the regulatory process for approval of novel biosimilar compounds.
27. European Medicines Agency. Assessment report for epoetin alfa Abseamed. 2007. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/ EPAR---Scientific-Discussion/ human/000727/WC500020666.pdf (accessed 26 August 2011).
28. European Medicines Agency. Assessment report for Epoetin alfa Hexal. 2007. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/ EPAR---Scientific-Discussion/human/ 000726/WC500028287.pdf (accessed 26 August 2011).
29. European Medicines Agency. Assessment report for epoetin alfa Binocrit. 2007. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/ EPAR---Scientific-Discussion/human/ 000725/WC500053615.pdf (accessed 26 August 2011).
30. European Medicines Agency. Assessment report for epoetin zeta Retacrit. 2007. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/ EPAR---Scientific-Discussion/human/ 000872/WC500054374.pdf (accessed 26 August 2011).
31. European Medicines Agency. Assessment report for epoetin zeta Silapo. 2007. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/ EPAR---Scientific-Discussion/human/ 000760/WC500050914.pdf (accessed 26 August 2011).
32. European Medicines Agency. Assessment report for Tevagrastim. 2008. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR--- Public-assessment-repor t /human/ 000827/WC500036667.pdf (accessed 26 August 2011).
33. European Medicines Agency. Assessment report for Zarzio. 2008. Available from: http://www.ema.europa.eu/docs/en-GB/document- l ibrar y/EPAR---Publ ic-assessment-repor t /human/ 000917/WC500046528.pdf (accessed 26 August 2011).
34. European Medicines Agency. Assessment report for Nivestim. 2010. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR--- Public-assessment-repor t /human/ 001142/WC500093664.pdf (accessed 26 August 2011).
35. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies. London, UK: 2010. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 11/WC500099361.pdf (accessed 26 August 2011).
36. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21(Suppl 5):v9-12.
37. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Oncologie. 2011;13:222-33.
38. Simoens S. Biosimilar medicines and cost-effectiveness. Clinico- Economics Outcomes Res. 2011;3:29-36.
39. Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010; 49:33-4.
40. Zuniga L, Calvo B. Biosimilars - the way forward. Hosp Pharm Europe. 2010;50:33-4.*This article lists the main differences between biosimilars and generic drugs in a very comprehensive manner.
41. European Generic Medicines Association. The future of pharmaceuticals: generic medicines enhancing pharmaceutical competition and ensuring healthcare sustainability. October 2007. Available from: http://www.egagenerics.com/doc/ ega-FuturePharmaceuticals. pdf (accessed 26 August 2011).
42. Aapro M, Cornes P, Abraham I. Comparative cost-effectiveness across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Practice. 2011 [Epub ahead of print]. *In this recent costefficiency analysis of the direct costs a buyer or payer would incur when purchasing or covering original or biosimilar filgastrim for the treatment of patients treated with highly risk neutropenia- induced chemotherapy regimens shows that the biosimilar compound is the most cost-efficient approach to reduce the incidence of febrile neutropenia in chemotherapy-treated patients.
43. Malik A. Biosimilars: perception, cost and the impact on biotech innovation. Pharmaceutical Technology Europe. 2010;22(issue 9). Available from: http://www.pharmtech.com/ptedigital0810 (accessed 2 September 2011).
44. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96:937-42.*Statement of one of the most recognized scientific societies in Europe regarding of the use of biosimilars in the practical setting.
45. Carrato A, Paz-Ares Rodríguez L, Rodríguez Lescure A, et al. Spanish Society of Medical Oncology (SEOM). Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. Clin Transl Oncol. 2009;11:446-54.*Spanish guidelines on the use of granulocyte growth factors agents.
46. Alberola Candel V, Carrato Mena A, Díaz-Rubio García E, et al. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clin Transl Oncol. 2009;11:727-36.*Spanish guidelines on the use of erythropoietins concurrent with chemotherapy.